SIE

213.85

+3.31%↑

AIR.FR

167.14

+3.8%↑

ENR.DE

150.45

+3.69%↑

RHM

1,573

+8.67%↑

HO

266.6

+5.67%↑

SIE

213.85

+3.31%↑

AIR.FR

167.14

+3.8%↑

ENR.DE

150.45

+3.69%↑

RHM

1,573

+8.67%↑

HO

266.6

+5.67%↑

SIE

213.85

+3.31%↑

AIR.FR

167.14

+3.8%↑

ENR.DE

150.45

+3.69%↑

RHM

1,573

+8.67%↑

HO

266.6

+5.67%↑

SIE

213.85

+3.31%↑

AIR.FR

167.14

+3.8%↑

ENR.DE

150.45

+3.69%↑

RHM

1,573

+8.67%↑

HO

266.6

+5.67%↑

SIE

213.85

+3.31%↑

AIR.FR

167.14

+3.8%↑

ENR.DE

150.45

+3.69%↑

RHM

1,573

+8.67%↑

HO

266.6

+5.67%↑

Search

LISI.

Atidarymo kaina

SektoriusPramonės sektorius

54.5 5.62

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

51.8

Max

54.7

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-14M

25M

Pardavimai

-240M

769M

P/E

Sektoriaus vid.

37.059

57.257

Dividendų pajamingumas

0.93

Pelno marža

3.22

Darbuotojai

9,537

EBITDA

-33M

106M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+21.33% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.93%

2.27%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-539M

2.3B

Ankstesnė atidarymo kaina

48.88

Ankstesnė uždarymo kaina

54.5

Naujienos nuotaikos

By Acuity

83%

17%

385 / 405 reitingas Industrials

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

LISI. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-31 23:31; UTC

Karštos akcijos

Stocks to Watch: Nike, RH, NCino

2026-03-31 22:35; UTC

Uždarbis

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

2026-04-01 00:00; UTC

Įsigijimai, susijungimai, perėmimai

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

2026-03-31 23:50; UTC

Įsigijimai, susijungimai, perėmimai

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

2026-03-31 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

2026-03-31 23:33; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

2026-03-31 23:21; UTC

Uždarbis

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

2026-03-31 23:14; UTC

Rinkos pokalbiai
Uždarbis

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

2026-03-31 23:12; UTC

Rinkos pokalbiai

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Loss Widens >000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

2026-03-31 21:46; UTC

Įsigijimai, susijungimai, perėmimai

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

2026-03-31 21:36; UTC

Rinkos pokalbiai

West African Resources's Costs Higher Than Bull Expected -- Market Talk

2026-03-31 21:35; UTC

Uždarbis

Nike Expects China Sales Down 20% in 4Q, CFO Says

2026-03-31 21:35; UTC

Uždarbis

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

2026-03-31 21:35; UTC

Uždarbis

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

2026-03-31 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

2026-03-31 21:33; UTC

Uždarbis

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

2026-03-31 21:32; UTC

Uždarbis

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

2026-03-31 21:28; UTC

Uždarbis

Nike Expects to End 4Q With Elevated Inventory, CFO Says

2026-03-31 21:26; UTC

Uždarbis

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

2026-03-31 21:25; UTC

Uždarbis

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

2026-03-31 21:24; UTC

Rinkos pokalbiai
Uždarbis

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

2026-03-31 21:22; UTC

Uždarbis

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

2026-03-31 21:22; UTC

Uždarbis

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

2026-03-31 21:21; UTC

Uždarbis

Nike's Digital Channel Still Too Promotional, CFO Says

2026-03-31 21:20; UTC

Uždarbis

Nike CEO: Converse Remains Important to Portfolio

Akcijų palyginimas

Kainos pokytis

LISI. Prognozė

Kainos tikslas

By TipRanks

21.33% į viršų

12 mėnesių prognozė

Vidutinis 62 EUR  21.33%

Aukščiausias 62 EUR

Žemiausias 62 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines LISI. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

27.7 / 28.3Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

385 / 405 reitingas Pramonės sektorius

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę LISI.

Lisi S.A. provides assembly and component solutions for the aerospace, automotive, and medical sectors in France and internationally. It operates through three divisions: LISI Aerospace, LISI Automotive, and LISI Medical. The company offers aeronautic fastener solutions; structural components and parts for aircraft, helicopters, and airplanes; air conditioning and pressurization products, actuation and power components, helicopter rotors, landing gear structures, tanks and accumulators, and wheels and brakes; fan blades, outlet guide vanes, compressor blades, fixed vanes, variable vanes, disks, blisks, impellers, gears, inner and outer rings, and housings, as well as accessories and equipment, hot and cold section products for jet engines and turboshafts; and defense and space products. It also provides threaded fasteners, including screws, bolts, nuts, washers, special parts, etc. for industrial and automotive systems; clipped solutions, such as panel and trim fasteners, clipped nuts and screws, fasteners and connectors for cables and tubes, anti-creep rings, etc.; and braking systems, seating, occupant safety systems, fuel system components, etc. In addition, the company offers reconstruction implants and instruments, and spine and orthopedic implants; components and instruments for manual or robotic mini-invasive surgery; and components for laparoscopy, endoscopy, cardiovascular, neuro-cerebral surgery, etc. The company was formerly known as GFI Industries and changed its name to Lisi S.A. in 2002. The company was founded in 1777 and is headquartered in Belfort, France.
help-icon Live chat